Search results
Showing 1 to 15 of 318 results for eq-5d
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our position on use of the EQ-5D-5L valuation set for England
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.
Prucalopride for the treatment of chronic constipation in women (TA211)
Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.
Tofacitinib for moderately to severely active ulcerative colitis (TA547)
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
values using directly observed health-related quality of life values (such as EQ 5D scores) in patients with myelodysplastic syndromes,...
Evidence-based recommendations on the bisphosphonates alendronic acid, ibandronic acid, risedronate sodium and zoledronic acid for treating osteoporosis.
effect of treatment using preference-based measures (such as use of the EQ-5D questionnaire). Any explanatory notes(if applicable) The...
NICE research projects and partners.
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating paroxysmal nocturnal haemoglobinuria in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
Evidence-based recommendations on aflibercept (Eylea) for treating sight problems caused by macular oedema from central retinal vein occlusion in adults.